Imricor benefits as elective surgery resumed in German

2021-03-09 02:04:32 (AET) by Ring Zhang   706


Imricor Medical Systems (ASX: IMR), an ASX-listed global cardia ablation product producer, has announced today that one of its collaboration partners in Europe, the Helios Leipzig Heart Centre, has resumed elective surgery.

Imricor Medical Systems (ASX: IMR), an ASX-listed global cardia ablation product producer, has announced today that one of its collaboration partners in Europe, the Helios Leipzig Heart Centre, has resumed elective surgery.

text

The German medical centre has signed a purchase agreement with Imricor in September 2020 to perform their ablation procedures using Imricor’s products.

While general lockdowns across Germany have been extended until 28 March, elective procedures at the Leipzig Heart Centre are no longer prohibited, according to Professor Gerhard Hindricks, Head of Electrophysiology at the Heart Centre.

This is the second time a IMR collaborative partner has announced the restart of elective procedures this quarter, following the announcement in February this year regarding surgery restriction lifted in Maastricht University Medical Centre+ in the Netherlands.

text

A bit intro about Imricor

Imicor is a leading developer of innovative MRI-compatible medical devices which are used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.


标签:

声明:这些资讯属于事实信息,仅供参考,不应被视为投资建议或用于投资决策

版权所有,转载需注明出处:61 澳洲财经资讯 news.61financial.com.au

商务合作请联系 support@61financial.com.au


61 澳洲财经资讯邮件订阅服务,每日为您推荐最新澳洲财经资讯


推广

cover
锂勘探商Hawkstone发出6月季报,积极推进分拆金矿IPO

Hawkstone Mining Limited (ASX:HWK) 公布截至2021年6月30日的季度活动报告。Big Sandy锂项目矿化材料的成功选矿试验工作表明,预处理量有可能显著减少。此前,该公司在2021年3月季度成功产出99.8%的电池级锂。HWK同时还计划分拆其重要黄金和金铜资产,成立一个独立的公司Diablo Resources Ltd,并在澳大利亚证券交易所独立上市。

cover
健康美容科技公司Wellfully的RÉDUIT美容胶囊的皮肤补水性能优于对照数倍

健康美容科技公司Wellfully Limited (ASX: WFL) 今日发出公告,称已完成旗下护肤护发品牌“叡蒂”设备的配用胶囊RÉDUIT's skinpod™的水化性能对比测试。测试由一所位于西澳珀斯的皮肤实验室完成,是一项针对“强力补水胶囊”Hydro Boost和“美白补水胶囊”Pearl Diffusion Skinpods™的体内补水性能测试。

相关文章

cover
医疗器械开发商Imricor产品获得澳洲TGA认证

医疗器械开发商Imricor Medical Systems, Inc.(ASX:IMR) 今日发出公告,称拓展取得重要的里程碑——其开发的Advantage-磁共振电生理记录仪/刺激器系统 (记录仪/刺激器) 系统获得了澳大利亚药监局TGA的批准。TGA目前也在对该公司配套的Vision-MR消融导管进行审查。

cover
心脏消融设备公司Imricor签署其第十个iCMR实验室站点

可视化心脏消融设备公司Imricor Medical Systems,Inc.( ASX:IMR)宣布,已与德国柏林布赫Helios综合性医院(Helios Hospital Berlin-Buch)签署协议,成为第十个建立iCMR(介入性心脏磁共振成像)实验室的临床站点,将采用Imricor的产品在由MRI引导的环境下进行可视化的心脏消融手术。

cover
医疗设备开发商Imricor发出季度报告,三大市场扩展策略全力推进

磁共振引导心脏消融产品的全球领导者Imricor Medical Systems (ASX:IMR) 今日发布其截至2021年6月30日的季度现金流报告并提供财务和运营业绩的季度更新。季度内,该公司新增一个新站点——Helios Hospital Berlin-Buch。公司表示,虽然其分销管道仍然强劲,但由于冠状病毒病 (COVID-19) 带来的长期影响,以及6月和7月的接种率低于预期,新iCMR站点的合同签署进度比预期要慢。